Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Events Timeline

(ET)

2026-02-22

14:00:00

Abivax Presents Clinical Data for Obefazimod

2026-01-12 (ET)

2026-01-12

10:30:00

Abivax Shares Up 5% as Eli Lilly Plans $17.5B Acquisition

2026-01-12

08:50:00

Starfighters Space Borrow Rate Increases to 282.66%

News

8.5

02-27Fool

PinnedReasons Behind Abivax's 1000% Stock Surge

9.0

02-21NASDAQ.COM

Abivax Presents New Findings on Obefazimod at ECCO Congress

8.5

02-21Newsfilter

Abivax Presents Obefazimod's First Evidence of Anti-Fibrotic Activity

8.5

02-11Fool

Eli Lilly's Decade of Market Dominance

5.0

02-11NASDAQ.COM

Eli Lilly Sets High Bar, Competitors Follow Suit

6.5

01-30Fool

Investment Comparison: AbbVie vs. Abivax

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Wedbush

initiated

$110

AI Analysis

2026-02-24

Reason

Wedbush

Price Target

$110

AI Analysis

2026-02-24

initiated

Reason

Wedbush initiated coverage of Abivax with an Underperform rating and $110 price target.

Wedbush

Underperform

initiated

$110

2026-02-24

Reason

Wedbush

Price Target

$110

2026-02-24

initiated

Underperform

Reason

As previously reported, Wedbush initiated coverage of Abivax with an Underperform rating and $110 price target. The firm notes Abivax is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-mediated diseases. Wedbush urges caution on speculation around M&A rumors, and recommends investors either wait for Q2 data or take profits at current levels, given substantial downside risk if a deal should fail to materialized after the Q2 readout.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is -41.67, compared to its 5-year average forward P/E of -8.26. For a more detailed relative valuation and DCF analysis to assess Abivax SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.26

Current PE

-41.67

Overvalued PE

4.53

Undervalued PE

-21.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.76

Current EV/EBITDA

-41.04

Overvalued EV/EBITDA

14.55

Undervalued EV/EBITDA

-42.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

283.00

Current PS

295.08

Overvalued PS

978.86

Undervalued PS

-412.86

Financials

AI Analysis

Annual

Quarterly

Whales Holding ABVX

Westfield Capital Management Company, L.P.

Boothbay Fund Management, LLC

Paradigm Biocapital Advisors LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 114.8 USD — it has decreased -5.34

What is Abivax SA (ABVX)'s business?

What is the price predicton of ABVX Stock?

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is150.71 USD with a low forecast of 131.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of March 02 2026.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 9.59B USD.

ABVX Overview

ABVX Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding ABVX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

What is Abivax SA (ABVX)'s business?

What is the price predicton of ABVX Stock?

What is Abivax SA (ABVX)'s revenue for the last quarter?

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

How many employees does Abivax SA (ABVX). have?

What is Abivax SA (ABVX) market cap?